Figure 2. Associations of baseline characteristics with an absolute decline in FVC >5% predicted or death over 52 weeks in patients with early and/or inflammatory SSc and/or severe skin fibrosis at baseline in the placebo group of the SENSCIS trial. Baseline variables were treated as continuous terms unless indicated otherwise. *OR shown per 1-unit increase for continuous variables. ATA, anti-topoisomerase I antibody; AUC, area under the receiver operating characteristic curve; CRP, C reactive protein; DLco, diffusion capacity of the lung for carbon monoxide; FVC, forced vital capacity; GERD, gastro-oesophageal reflux disease; HRCT, high-resolution computed tomography; ILD, interstitial lung disease; mRSS, modified Rodnan skin score; SSc, systemic sclerosis.